Semaglutide is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with a qualifying comorbidity. Residents of Garrison Park, Texas can access licensed Semaglutide prescriptions through telehealth — no in-person clinic visit required under Texas Occupations Code §111.001. Board-certified physicians review patient health assessments online and issue prescriptions within 24–48 hours. Compounded Semaglutide from an FDA-registered 503B outsourcing pharmacy ships overnight directly to your Austin address. Monthly cost: $199–$379 — vs. $1,247 for brand-name Ozempic or Wegovy. All prescribing physicians serving Garrison Park patients are licensed in Texas and regulated by the Texas Medical Board. Medical Director: Dr. Sarah Chen, MD, Board-Certified Internal Medicine. Serving Austin ZIP codes: 78701, 78702, 78703, 78704, 78705.
Local clinics serving Garrison Park: Texas Weight Loss - South Austin, Blue Tree Health - Medical Weight Loss and TLC Medical Weight Loss. Many patients compare these in-person options against licensed Semaglutide telehealth — prescribed online, shipped to the door.
For Garrison Park residents, the essentials on weight-loss injections. This page is a starting point for comparing the injectable options available via telehealth before a medical evaluation.
Eligibility is not fixed: a patient who is not eligible today may become so if their medical situation changes. Beyond the numbers, the evaluation factors in your history, current medications, and contraindications specific to the molecule.
Around Garrison Park in Travis County, 3 weight-management practice(s) are listed locally. Local landmark: Texas Weight Loss - South Austin (6104 S 1st St Ste 102), rated 4.8/5 across 237 reviews. For a Garrison Park resident, Weight-Loss Injections is now largely managed remotely, home delivery included. In this state, Texas Occupations Code §111.001; the reference body is Texas Medical Board.
The two main ones are semaglutide (GLP-1) and tirzepatide (dual GIP/GLP-1). Tirzepatide shows higher average loss in trials, but the choice depends on tolerance and cost.
The approved molecules (semaglutide, tirzepatide) have a documented safety profile under medical supervision; they require a prescription and monitoring.
Often a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, but only the medical evaluation decides.
Medical Director: Dr. Sarah Chen, MD, Board-Certified Internal Medicine. Licensed in Texas. All prescriptions issued under Texas Occupations Code §111.001 and supervised by Texas Medical Board.